Evidence map›Paper›PMID 36044525›Full record

ArticlePloS one2022

AI-based search for convergently expanding, advantageous mutations in SARS-CoV-2 by focusing on oligonucleotide frequencies.

Toshimichi Ikemura, Yuki Iwasaki, Kennosuke Wada, Yoshiko Wada, Takashi Abe

Abstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Toshimichi IkemuraNagahama Institute of Bio-Science and Technology, Nagahama, Shiga-ken, Japan.ORCID 0000-0001-9931-172X
Yuki IwasakiNagahama Institute of Bio-Science and Technology, Nagahama, Shiga-ken, Japan.
Kennosuke WadaNagahama Institute of Bio-Science and Technology, Nagahama, Shiga-ken, Japan.
Yoshiko WadaNagahama Institute of Bio-Science and Technology, Nagahama, Shiga-ken, Japan.
Takashi AbeFaculty of Engineering, Niigata University, Niigata-ken, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Among mutations that occur in SARS-CoV-2, efficient identification of mutations advantageous for viral replication and transmission is important to characterize and defeat this rampant virus. Mutations rapidly expanding frequency in a viral population are candidates for advantageous mutations, but neutral mutations hitchhiking with advantageous mutations are also likely to be included. To distinguish these, we focus on mutations that appear to occur independently in different lineages and expand in frequency in a convergent evolutionary manner. Batch-learning SOM (BLSOM) can separate SARS-CoV-2 genome sequences according by lineage from only providing the oligonucleotide composition. Focusing on remarkably expanding 20-mers, each of which is only represented by one copy in the viral genome, allows us to correlate the expanding 20-mers to mutations. Using visualization functions in BLSOM, we can efficiently identify mutations that have expanded remarkably both in the Omicron lineage, which is phylogenetically distinct from other lineages, and in other lineages. Most of these mutations involved changes in amino acids, but there were a few that did not, such as an intergenic mutation.

Indexed as

COVID-19MutationOligonucleotidesSARS-CoV-2Artificial IntelligenceGenome, ViralHumansMachine LearningPhylogenySpike Glycoprotein, CoronavirusOligonucleotidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID36044525
PMCPMC9432735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.